Company News-Bio-Thera Solutions, Ltd.

The European Commission (EC) Approves Bio-Thera Solutions’ BAT2206 (USYMRO®, ustekinumab), a biosimilar referencing Stelara®

2025-08-26

Guangzhou, China– August , 2024 – Inc. “The EC approval of BAT2206 is anothersignificant accomplishment for Bio-Thera as...

查看详情

10-092024

Bio-Thera and Richter Execute Exclusive Commercialization Agreement for BAT2206, a Proposed Stelara® Biosimilar, for EU countries, UK, Switzerland and other selected countries

Guangzhou, China/Budapest, Hungary– # October 9,2024 – Bio-Thera Solutions (688177:SH; “Bio-Thera”), a commercial-stageb...
09-112024

Bio-Thera Solutions and Biogen Publish Phase 3 Clinical Trial Data for TOFIDENCETM (BAT1806/BIIB800), an approved Biosimilar referencing tocilizumab in Arthritis Research & Therapy

Comparable clinical efficacy and safety in Treatment Period 2 (TP2, Week 24-48) is maintained after switch from referenc...
08-162024

Bio-Thera Solutions and Pharmapark Further Expand Partnership in Russia and other CIS Countries with Addition of BAT2306, a Cosentyx® Biosimilar

GUANGZHOU, China and MOSCOW, Russia --- Bio-Thera Solutions, Ltd (688177:SH), a commercial-stagebiopharmaceutical compan...

上一页 ···6 7 8 9 10 ··· 下一页